Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location

Melanoma Clinical Trials

A listing of Melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (296) clinical trials

Characterization of the Melanoma-Specific Immune Response

The aim of the study is to in-vitro characterize and expand T cells specific for melanoma-derived antigens. Peripheral blood with be collected from 20 volunteers with biopsy proven melanoma and 10 age matched controls. Blood will be collected prior to the initiation of chemotherapy. There will be no more than ...

Phase

Investigate the Diagnostic Value and Possibilities of OCT in Non-Melanoma Skin Cancer.

Optimal management of skin malignancies relies on early and accurate diagnosis. The reference standard in skin cancer is biopsy and histopathological assessment from a clinical suspicious skin lesion. The clinical diagnosis of skin cancer has sensitivity ranging from 50% to 90 % and specificity around 70% to 80% depending on ...

Phase

Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma

Serum is taken from each melanoma patient at every follow up after signed concent. With ELISA the marker MIA is evaluated. An increase of MIA serum level will lead to search for metastasis by oncologists.

Phase N/A

Study of Families With Melanoma

OBJECTIVES: Primary - Determine what lifestyle factors and which genes govern relapse from melanoma. Secondary - Compare sun exposure and genes that cause melanoma in patients with melanoma vs healthy participants. - Assess how unusual moles relate to sun exposure and genes that cause melanoma. OUTLINE: This is a multicenter, ...

Phase N/A

Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma

OBJECTIVES: - Determine the incidence and etiologic significance of variants of known melanoma susceptibility genes (MSGs) in families with multiple cases of melanoma. - Determine the proportion of multiple-case families that are explained by high-penetrance mutations in known MSGs. - Determine the proportion of multiple-case families that are explained by ...

Phase N/A

Sunitinib Tamoxifen and Cisplatin in Treating Patients With High-Risk Ocular Melanoma

OBJECTIVES: - Determine the effect of adjuvant sunitinib malate, tamoxifen citrate, and cisplatin on disease-free survival and overall survival of patients with high-risk ocular melanoma who have undergone primary therapy. - Determine the toxicity of this regimen in these patients. OUTLINE: This is a pilot study. Patients receive oral sunitinib ...

Phase

Sorafenib Tamoxifen and Cisplatin in Treating Patients With High-Risk Stage III Melanoma

OBJECTIVES: - Compare relapse-free and overall survival of patients with high-risk stage III melanoma receiving adjuvant sorafenib tosylate, tamoxifen citrate, and cisplatin vs historical data from patients treated with tamoxifen citrate and cisplatin. - Compare the toxicity of these regimens in these patients. OUTLINE: This is a pilot study. Patients ...

Phase

Sorafenib Bevacizumab and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma

OBJECTIVES: - To determine the maximum tolerated dose of sorafenib tosylate when administered with bevacizumab and oxaliplatin. - To determine the effect of this treatment regimen on the complete and partial response rate in patients with metastatic melanoma. - To determine the effect of this treatment regimen on the progression-free ...

Phase

A Study Comparing the Effects on Melanoma With High Dose IFN Alone vs Cisplatin Velban DTIC IL2 IFN and G CSF

To compare the overall survival and disease-free survival between patients with high risk melanoma who recieve high dose interferon Alphe 2b versus Cisplatin, Vinblastine, DTIC plus IL-2 and Interferon. To evaluate the toxicities of these two regimens in the patient population. To investigate the predictive value for disease (OS and ...

Phase

Ipilimumab in Young Patients With Advanced or Refractory Solid Tumors

OBJECTIVES: Primary - To determine the tolerance and toxicity profile of ipilimumab at a range of doses up to, but not exceeding, the highest dose tolerated in patients 21 years of age or younger with advanced or refractory solid tumors. - To assess the pharmacokinetics of ipilimumab in patients with ...

Phase